References
Feldmeyer L, Mylonas A, Demaria O, et al. Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris. JAMA Dermatol 2017;153:304–8.
Schuster D, Pfister-Wartha A, Bruckner-Tuderman L, Schempp CM. Successful treatment of refractory pityriasis rubra pilaris with secuk-inumab. JAMA Dermatol 2016;152:1278–80.
Gauci ML, Jachiet M, Gottlieb J, et al. Successful treatment of type II pityriasis rubra pilaris with secukinumab. JAAD Case Rep 2016;2:462–4.
Hanfstingl K, Pekar-Lukacs A, Motz R, Guenova E, Hoetzenecker W. Successful treatment of pityriasis rubra pilaris with ixekizumab. Case Rep Dermatol 2018;10:97–100.
Chowdhary M, Davila U, Cohen DJ. Ustekinumab as an alternative treatment option for chronic pityriasis rubra pilaris. Case Rep Dermatol 2015;7:46–50.
Craiglow BG, Boyden LM, Hu R, et al. CARD14-associated papu-losquamous eruption: a spectrum including features of psoriasis and pityriasis rubra pilaris. J Am Acad Dermatol 2018;79:487–94.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Chastagner, M., Hoelt, P., Kanitakis, J. et al. Successful treatment of TNFα inhibitor-resistant pityriasis rubra pilaris with ixekizumab and acitretin. Eur J Dermatol 29, 218–220 (2019). https://doi.org/10.1684/ejd.2019.3502
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2019.3502